Sarcoma  >>  Fotivda (tivozanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
NCT01782313: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
58
US
tivozanib, AV-951, oral VEGF receptor tyrosine kinase inhibitor AV-951, laboratory biomarker analysis
Northwestern University, AVEO Pharmaceuticals, Inc.
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
05/15
12/16
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
12/24
12/25

Download Options